Search | Clinical Trials Finder

Conditions: HIV-1 Infection
Interventions: blood drawing; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Human Immunodeficiency Virus
Interventions: Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 145
States / cities: Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: No intervention; Observational study; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more

Conditions: HIV Disease
Interventions: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: 3BNC117, Antiretroviral Treatment Interruption; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: HIV Infections, AIDS
Interventions: raltegravir, efavirenz; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Sacramento, California

Conditions: HIV, Acute HIV Infection
Interventions: Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV
Interventions: HXTC infusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Human Immunodeficiency Virus (HIV) Infection, Hypercholesterolemia
Interventions: Soy Pretzel, Wheat Pretzel; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections
Interventions: KP-1461; Drug
Lead sponsor: Koronis Pharmaceuticals.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 9
States / cities: Bradenton, Florida • Miami, Florida • West Palm Beach, Florida + 6 more

Conditions: HIV Infections
Interventions: DTG/3TC FDC, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 19
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Mental Health Disorder, Substance Use Disorder, Stigmatization, Implementation Science
Interventions: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum, You℞ Decision prescribing platform; Behavioral · Device
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Decatur, Georgia • Duluth, Georgia

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Berkeley, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions: Crofelemer delayed-release tablets 125mg; Drug
Lead sponsor: Napo Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Tustin, California • Stratford, Connecticut • Springfield, Massachusetts

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: HIV-1
Interventions: 3BNC117-LS, 10-1074-LS, Sterile Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: HIV Infection, Hyperlipidemia
Interventions: Atazanavir, current antiretroviral regimen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: AIDS, HIV Infections
Interventions: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART; Other · Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 29
States / cities: Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more

Conditions: HIV Infection
Interventions: Pegylated Interferon Alpha 2b (PEGINTRON); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: HIV-1 Infection
Interventions: Vorinostat, HXTC; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infection
Interventions: DOR/ISL, ART; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more

Search by objective public record fields.

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

A Study of the Safety and Antiretroviral Activity of 3BNC117

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

CSP #512 - Options in Management With Anti-Retrovirals

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)